Cytotoxicity and Immunomodulatory Effects of Cannabidiol on Canine PBMCs: A Study in LPS-Stimulated and Epileptic Dogs DOI Creative Commons

Phannicha Kosukwatthana,

Oumaporn Rungsuriyawiboon, Jatuporn Rattanasrisomporn

et al.

Animals, Journal Year: 2024, Volume and Issue: 14(24), P. 3683 - 3683

Published: Dec. 20, 2024

Cannabidiol, the primary non-psychoactive phytocannabinoid found in cannabis, has generated significant research interest due to its potential for biological effects, such as anti-inflammatory, analgesic, immunomodulatory, and anticonvulsant properties. Several studies have demonstrated of CBD alter inflammatory cytokines; however, data on CBD’s effects cell viability pro-inflammatory cytokines target animals, dogs, are limited. Therefore, this study, we investigated modulation cytokines, interleukin (IL)-1β, IL-6, tumor necrosis factor-α (TNF-α), canine PBMCs stimulated with LPS. To evaluate effect neuroinflammation epilepsy pathology, an independent study five refractory epileptic dogs co-treated 30 days was conducted. The current findings revealed that concentrations 16 µg/mL had a statistically calculated IC50 15.54 µg/mL. LPS-stimulated tended be dose-dependent, 5–30 μg/mL resulting decreased production tested cytokines. Considering cytokine by from modulate immune responses provide benefits when used combination antiepileptic drugs. provided evidence cytotoxicity alteration PBMCs.

Language: Английский

A Preliminary Evaluation of the Comparative Efficacy of Gel-Based and Oil-Based CBD on Hematologic and Biochemical Responses in Dogs DOI Creative Commons

Wassana Puttharaksa,

Rangsun Charoensook,

Rongdej Tungtrakanpoung

et al.

Veterinary Sciences, Journal Year: 2025, Volume and Issue: 12(4), P. 342 - 342

Published: April 7, 2025

Cannabidiol (CBD) has gained popularity in veterinary medicine for its potential to alleviate stress, pain, and inflammation dogs. However, oral administration is limited by hydrophobicity, variable absorption, extensive first-pass metabolism, which requires optimized delivery methods enhance efficacy. This study investigated the effects of daily supplementation CBD oil gel (each at 4 mg/kg), compared a placebo, over 14 days shelter dogs subjected solitary confinement-induced stress. Both formulations appeared safe under conditions, with no adverse on hematological biochemical parameters. Post-stress cortisol levels were significantly lower CBD-treated groups controls, CBD-infused showing pattern toward greater attenuation. Multivariate analysis revealed distinct blood profile shifts dogs, PCA loadings indicating associations between lymphocyte percentages IgG levels. These findings support gel-based as promising strategy stress modulation Further studies should explore pharmacokinetics long-term immune optimize applications.

Language: Английский

Citations

1
The Potential of Cannabidiol for Treating Canine Atopic Dermatitis DOI Creative Commons
Ana Filipa Bizarro Camões, Vanessa Schmidt, Beatriz Fernandes

et al.

Veterinary Sciences, Journal Year: 2025, Volume and Issue: 12(2), P. 159 - 159

Published: Feb. 12, 2025

Atopic dermatitis is prevalent in humans (hAD) and dogs (cAD) profoundly impacts the patients’ quality of life. The increasing number new drugs development for atopic indicates both need potential precision medicine to generate an optimised benefit–risk therapeutic plan. Cannabidiol (CBD), known its anti-inflammatory antipruritic properties, shows promise hAD cAD management, prompting exploration cannabinoids (CBs) CBD as tools. In fact, encouraging results on benefits using have been published, along with safety evaluations that reveal generally well tolerated dogs. However, limited placebo-controlled trials dosage variations pose barriers hinder definitive conclusions. Challenges product stability, inconsistent formulations, legal ambiguities highlight standardised CBD-based products research commercial uses. complex landscape further complicates accessibility regulation. Despite these challenges, emerging a avenue urging high-quality research, clarity. This brief review provides valuable insights into CBs cAD, compared hAD, emphasising importance rigorous unambiguous regulation successful integration veterinary dermatology.

Language: Английский

Citations

0
Pharmacokinetics of Non-Psychotropic Phytocannabinoids DOI Creative Commons

Mariana Lacerda,

Andreia Carona,

Sara Castanheira

et al.

Pharmaceutics, Journal Year: 2025, Volume and Issue: 17(2), P. 236 - 236

Published: Feb. 12, 2025

Cannabinoids are widely recognized for their potential therapeutic effects, making them significant and valuable candidates medical research applications across various fields. This review aims to analyze the pharmacokinetics of Cannabidiol (CBD), Cannabigerol (CBG), Cannabichromene (CBC), along with corresponding acidic forms, Cannabidiolic acid (CBDA), Cannabigerolic (CBGA), Cannabichromenic (CBCA). Among these cannabinoids, CBD is most extensively studied. Nevertheless, involving all mentioned cannabinoids has shown that pharmacokinetic parameters highly variable, depending significantly on factors such as dose, formulation, route administration, diet. Furthermore, challenges brain penetration first-pass metabolism have been highlighted. In conclusion, this demonstrates progress in understanding non-psychotropic cannabinoids. However, it also underscores need further research, particularly CBG, CBC, respective gap being clinical investigations. Expanding studies essential facilitate optimized use treatments.

Language: Английский

Citations

0
Pharmacokinetics of a single oral administration of two cannabidiol formulations in fed and fasted horses DOI Creative Commons
Alessandra Di Salvo, Marilena Bazzano, Giorgia Della Rocca

et al.

Frontiers in Veterinary Science, Journal Year: 2025, Volume and Issue: 12

Published: Feb. 19, 2025

Pain management in horses plays a pivotal role the therapeutic approach to several diseases. Horses have cannabinoid receptors at level of dorsal root ganglia, blood vessels, and synoviocytes that can be up or down- regulated by inflammatory conditions, justifying possible efficacy exogenous cannabinoids (i.e., phytocannabinoids) managing painful pathologies this animal species. However, current use supplements containing cannabidiol (CBD) equines is based on anecdotal evidence, without support sufficient pharmacokinetic studies. In humans, concentration peak CBD area under concentration-time curve (AUC) are both strongly influenced food administration. Also, equids, oral bioavailability some drugs meal but no information available about CBD. This study investigated pharmacokinetics following single administration two different formulations pure (oil paste), dosed 1 mg/kg, times oil paste were administered orally mg/kg eight healthy according cross over design, samples taken pre-fixed time-points for analyses. The obtained data did not allow statistically significant differences between (paste oil) feeding time (fed fasted status). treatment with paste, Cmax was achieved shorter range compared oily formulation, indicating it could better formulation consider future equine

Language: Английский

Citations

0
Endocannabinoid system and phytocannabinoids in the main species of veterinary interest: a comparative review DOI Creative Commons
Alessandra Di Salvo, Elisabetta Chiaradia, Monica Sforna

et al.

Veterinary Research Communications, Journal Year: 2024, Volume and Issue: 48(5), P. 2915 - 2941

Published: Aug. 20, 2024

Since the discovery of endocannabinoid system and due to empirical evidence therapeutic effects on several illnesses both in humans animals that follow administration exogenous cannabinoids (i.e., phytocannabinoids), numerous studies have been conducted. These investigations aimed identify expression distribution cannabinoid receptors healthy pathologic organs tissues different animal species define interactions phytocannabinoids with these receptors. In last decade, pharmacokinetics, efficacy tolerability many Cannabis derivatives formulations, mainly containing cannabidiol, main veterinary interest, also investigated. This manuscript summarizes findings reported by scientific published so far molecular mode action phytocannabinoids, localization tissues, as well dogs, cats, horses other interest. A deep knowledge issues is crucial for use purposes species.

Language: Английский

Citations

2
Cytotoxicity and Immunomodulatory Effects of Cannabidiol on Canine PBMCs: A Study in LPS-Stimulated and Epileptic Dogs DOI Creative Commons

Phannicha Kosukwatthana,

Oumaporn Rungsuriyawiboon, Jatuporn Rattanasrisomporn

et al.

Animals, Journal Year: 2024, Volume and Issue: 14(24), P. 3683 - 3683

Published: Dec. 20, 2024

Cannabidiol, the primary non-psychoactive phytocannabinoid found in cannabis, has generated significant research interest due to its potential for biological effects, such as anti-inflammatory, analgesic, immunomodulatory, and anticonvulsant properties. Several studies have demonstrated of CBD alter inflammatory cytokines; however, data on CBD’s effects cell viability pro-inflammatory cytokines target animals, dogs, are limited. Therefore, this study, we investigated modulation cytokines, interleukin (IL)-1β, IL-6, tumor necrosis factor-α (TNF-α), canine PBMCs stimulated with LPS. To evaluate effect neuroinflammation epilepsy pathology, an independent study five refractory epileptic dogs co-treated 30 days was conducted. The current findings revealed that concentrations 16 µg/mL had a statistically calculated IC50 15.54 µg/mL. LPS-stimulated tended be dose-dependent, 5–30 μg/mL resulting decreased production tested cytokines. Considering cytokine by from modulate immune responses provide benefits when used combination antiepileptic drugs. provided evidence cytotoxicity alteration PBMCs.

Language: Английский

Citations

0